ELIC — Elicera Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK199.54m
- SEK141.41m
- SEK10.86m
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application
Brief: Elicera Therapeutics Q2 Operating Loss SEK 6.3 Mln
Sweden's Elicera Therapeutics Q2 loss widens
Brief: Elicera Therapeutics Appoints Johan Liwing As New CEO
Brief: Elicera Consolidates Management, Starts CEO Transition
Brief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent
Brief: Elicera Therapeutics Provides Update On CARMA Study
Brief: Elicera Updates On Preclinical CAR T-Cell Program ELC-401 For Glioblastoma
Sweden's Elicera Q4 operating loss widens
Brief: Elicera Therapeutics Q4 Dividend SEK 0
Brief: Elicera Therapeutics: Final Data From Phase I/IIa Trial
Brief: Elicera Therapeutics Q3 Adjusted EPS Sek 0.01